Most of the cost in pharma trials is not due to safety testing, it is in testing whether it is effective and whether it is better than the competition.

I'm not really involved in pharma, but there seems to be a decent argument for selling the drug with provisional approval after safety has been established and collecting outcomes data for those who use provisional drugs https://reason.com/2018/02/02/right-to-try-fda-drug-trials/